T Munir
Overview
Explore the profile of T Munir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davids M, Lin K, Mohamed A, Munir T, Eyre T
Br J Haematol
. 2024 Nov;
206(1):33-43.
PMID: 39538975
The therapeutic paradigm for patients suffering from chronic lymphocytic leukaemia continues to rapidly evolve. Fixed duration therapies continue to develop using novel-novel non-chemotherapeutic combinations. B-cell lymphoma 2 (BCL2) inhibitors in...
2.
Barrett A, Appleby N, Dreau H, Fox C, Munir T, Eyre T
Blood Rev
. 2023 Dec;
64:101163.
PMID: 38097488
Richter transformation (RT) represents an aggressive histological transformation from chronic lymphocytic leukaemia, most often to a large B cell lymphoma. It is characterised by chemo-resistance and subsequent short survival. Drug...
3.
Fisher A, Goradia H, Martinez-Calle N, Patten P, Munir T
Front Oncol
. 2023 Mar;
13:1130617.
PMID: 36910619
Measurable residual disease (MRD) status in chronic lymphocytic leukemia (CLL), assessed on and after treatment, correlates with increased progression-free and overall survival benefit. More recently, MRD assessment has been included...
4.
Kendall W, Chengot P, Munir T, Moor J
Ann R Coll Surg Engl
. 2022 Jul;
105(1):91-93.
PMID: 35904328
Langerhans' cell histiocytosis (LCH) is a rare condition characterised by histiocyte proliferation leading to destructive granulomatous lesions. It may occur anywhere in the body but extraosseous manifestations affecting the head...
5.
Brown J, Hillmen P, OBrien S, Barrientos J, Reddy N, Coutre S, et al.
Leukemia
. 2017 Jun;
32(1):83-91.
PMID: 28592889
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic...
6.
Howard D, Munir T, McParland L, Rawstron A, Milligan D, Schuh A, et al.
Leukemia
. 2017 Mar;
31(11):2416-2425.
PMID: 28336937
ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontline therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). The...
7.
Munir T, Howard D, McParland L, Pocock C, Rawstron A, Hockaday A, et al.
Leukemia
. 2017 Feb;
31(10):2085-2093.
PMID: 28216660
ADMIRE was a multicenter, randomized-controlled, open, phase IIB superiority trial in previously untreated chronic lymphocytic leukemia. Conventional front-line therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Initial evidence...
8.
Worrillow L, Baskaran P, Care M, Varghese A, Munir T, Evans P, et al.
Oncogene
. 2016 Apr;
35(40):5328-5336.
PMID: 27041575
Chronic lymphocytic leukaemia (CLL) is the most common clonal B-cell disorder characterized by clonal diversity, a relapsing and remitting course, and in its aggressive forms remains largely incurable. Current front-line...
9.
Siraj Q, Waqar A, Rathore S, Munir T, Ahmed S
J Pak Med Assoc
. 1990 Dec;
40(12):283-8.
PMID: 2126567
Patients with haemolytic anaemias of different etiologies were investigated using the 51Cr red cell survival and surface counting technique. The study provided definitive information regarding the presence of a haemolytic...